CUVITRU is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years. CUVITRU is for subcutaneous use only.
Once a treatment decision has been made, there are different options for getting your patients started on treatment:
The information provided below can help ensure your patients are equipped with everything they need for an optimal administration experience.
CUVITRU is supplied in single-use vials containing the labeled amount of functionally active IgG. The components used in the packaging for CUVITRU are not made with natural rubber latex.1
|NDC Number||GRAMS PROTEIN|
|NDC Number||VOLUME||GRAMS PROTEIN|
The following information is intended to assist HCPs in selection of appropriate equipment in order to achieve the maximum infusion rate of 60 mL/h/site with CUVITRU. Takeda does not prefer, recommend, or attest to using any specific infusion pump or other ancillary devices. For the first two infusions of CUVITRU, the recommended infusion rate is 10-20 mL/hr/site. For subsequent infusions, the infusion rate may be increased to 60 mL/hr/site as tolerated (e.g., 60 mL/hr/site x 2 sites = 120 mL/hr).
Follow each infusion pump’s manufacturer guidelines before use and administration.
RMS Freedom Infusion System2,3
High-Flo Subcutaneous Safety Needle Sets™
EMED SCiG Infusion System4,5
Soft-Glide™ Needle Sets
When getting started on therapy, your patients will receive CUVITRU from a specialty pharmacy provider (SPP). Here are some considerations when working with an SPP:
Patient’s prescribed CUVITRU may receive it from an SPP. Check your patient’s insurance coverage to determine which SPP is within your patient’s network.
The following SPPs are authorized to dispense CUVITRU:
Inquire with specific SPPs for current status.
All product brands or trademarks are the property of their respective owners.
Review Important Safety Information, including contraindications and other specific warnings and precautions to consider when prescribing and monitoring patients treated with CUVITRU.